FINWIRES · TerminalLIVE
FINWIRES

K-Bro Linen Tops 第一季度业绩预期:受益于医疗保健行业增长,盈利和收入均大幅增长

By

-- K-Bro Linen (KBL.TO) 公布,受营收增长推动,第一季度调整后盈利同比增长 35%,超出分析师预期。 截至 2026 年 3 月 31 日的三个月内,剔除大部分一次性项目后,公司调整后盈利从去年同期的 340 万加元(合每股 0.33 美元)增至 460 万加元(合每股 0.36 美元),高于 FactSet 此前预测的每股 0.03 美元。 该季度营收同比增长 53%,从去年同期的 9100 万美元增至 1.391 亿美元,高于 FactSet 此前预测的 1.264 亿美元。其中,医疗保健业务营收从 2025 年第一季度的 5060 万美元增至 8470 万美元,增幅达 67.4%。酒店业务营收也从去年同期的 4040 万美元增至 5440 万美元。 2026财年,公司计划的资本支出(不包括使用权资产)预计在2000万美元至2200万美元之间(合并计算)。 “我们很高兴地宣布连续第八个季度业绩创下新高,这凸显了我们在加拿大和英国的战略性全国平台的优势。我们对Stellar Mayan的整合工作进展顺利,我们预计在未来12至24个月内将实现成本协同效应。我们将一如既往地致力于提供行业领先的服务,并成为客户值得信赖的合作伙伴。”首席执行官琳达·麦克柯迪表示。 公司股票在多伦多证券交易所收盘价为39.00美元,与前一日持平。

Related Articles

Asia

Anteris Technologies Enrolls First US Patients in PARADIGM Trial; Shares Up 6%

Anteris Technologies (ASX:AVR) has enrolled and successfully treated the first US patients in its PARADIGM global pivotal trial of the DurAVR transcatheter heart valve for severe calcific aortic stenosis, according to a Wednesday Australian bourse filing.The procedures were carried out at Montefiore Medical Center in New York, the filing added.The company's shares rose 6% in recent Wednesday trade.

$ASX:AVR
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ballard Power System Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price from CAD4.20 to CAD6.40, applying a price-to-sales multiple of 13x our 2026 sales-per-share view (CAD0.49 using a USD/CAD exchange rate of 0.73x). We adjust our 2026 loss per share (LPS) estimate to -USD0.19 from -USD0.23 and our 2027 LPS view to -USD0.11 from -USD0.15. BLDP reported Q1 2026 revenue of USD19.4M, up 26% Y/Y, driven by strong growth in rail (up 4,472% to USD5.1M) and stationary power (up 775% to USD5.2M), though Bus revenue declined 46% to USD6.8M due to delivery timing and EU funding delays. Q1 results showed encouraging metrics, and we see potential upside from major design wins with Wrightbus and Solaris for next-generation hydrogen bus platforms and a multiyear 50 MW agreement with New Flyer. However, its declining backlog remains a concern. The 12-month order book declined 2% to USD52.8M, while the total backlog fell 5% to USD112.9M. We applaud improving gross margin trends, reflecting successful execution of its cost reduction initiatives.

$BLDP
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ballard Power System Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price from $3.00 to $4.70, applying a price-to-sales multiple of 13x our 2026 sales-per-share view of $0.36. We adjust our 2026 loss per share (LPS) estimate to -$0.19 from -$0.23 and our 2027 LPS view to -$0.11 from -$0.15. BLDP reported Q1 2026 revenue of $19.4M, up 26% Y/Y, driven by strong growth in rail (up 4,472% to $5.1M) and stationary power (up 775% to $5.2M), though Bus revenue declined 46% to $6.8M due to delivery timing and EU funding delays. Q1 results showed encouraging metrics, and we see potential upside from major design wins with Wrightbus and Solaris for next-generation hydrogen bus platforms and a multiyear 50 MW agreement with New Flyer. However, its declining backlog remains a concern. The 12-month order book declined 2% to $52.8M, while the total backlog fell 5% to $112.9M. We applaud improving gross margin trends, reflecting successful execution of its cost reduction initiatives.

$BLDP